Please ensure Javascript is enabled for purposes of website accessibility

Surprise! Robinhood Investors Are Missing Out on These 2 High-Growth Stocks

By David Jagielski – Aug 15, 2020 at 8:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Both of these stocks have more than doubled this year, but neither makes Robinhood's Top 100.

Robinhood is a popular trading platform that often serves as a barometer of what's hot and what's not on the markets. Stocks that are among the most popular on Robinhood come from a variety of industries and risk levels, but most are primed for serious growth.

However, there are a couple of surprising omissions from the Robinhood Top 100, a continuously updated list of the most popular stocks on the platform. Teladoc Health (TDOC 3.10%) and Shopify (SHOP -2.00%) are two high-growth stocks that I'd expect to be popular among Robinhood investors, especially since both companies doubled their sales over the past two years and Robinhood captures a large millennial audience that follows burgeoning businesses.

1. Teladoc

Teladoc Health is currently the 212th most popular stock on the platform, according to Robintrack, which tracks the popularity of stocks on Robinhood. That's a surprise considering the virtual healthcare platform's success this year -- its share price is up more than 120% year-to-date. Teladoc's service allows patients with or without insurance to access a doctor via virtual visits, demand for which has soared amid the COVID-19 pandemic, as people shelter at home and avoid in-person trips to the doctor's office.

Excited investor.

Image source: Getty Images.

Teladoc recently released its second-quarter numbers, reporting year-over-year sales growth of 85% for the three-month period ending June 30. The number of virtual visits conducted through the platform grew from 908 million in the year-prior to nearly 2.8 billion, an incredible 203% increase. There's still a lot of room for the company to grow, especially as COVID-19 remains a serious public concern. The challenge for Teladoc is to continue growing at more than 80% year-over-year. While that growth rate is probably unsustainable over the long term, it is not unreasonable for double-digit growth to continue indefinitely given the pandemic and patients' desire to minimize unnecessary travel.

The company has also been making headlines this summer. On August 5, Teladoc announced its planned $18.5 billion merger with Livongo Health, which is sure to drive even more growth in the future. Livongo, which is ranked at #178 on Robinhood and ahead of Teladoc, focuses on treating people with chronic conditions, specifically diabetes. Through its network of devices, patients have the ability to share their glucose readings with family members and health coaches. The deal extends Teladoc's reach into forming patients' day-to-day health habits and opens up a new consumer base. The merger is still subject to shareholder approvals but the companies expect the transaction to close by the fourth quarter. 

Teladoc has had a banner year thanks to the stay-at-home orders necessitated by the spread of COVID-19. But even once those orders subside, demand for telehealth services could remain strong as people continue to social distance. Favorable private and public reimbursement coverage and consumer satisfaction with the ease of virtual non-urgent appointments should also encourage future use. Market research company Global Market Insights forecasts that the market for telemedicine will grow at a compound annual growth rate (CAGR) of 19.3% until 2026, when it'll reach a value of more than $175 billion. That's up from $45 billion in 2019.

Potential company and industry growth is good news for investors. Teladoc is an already successful stock that's poised to shoot even higher.

2. Shopify

Shopify rings in at 118 on Robintrack, narrowly missing the Top 100. The Canadian e-commerce company is also experiencing an increase in demand, benefiting from more people staying home and purchasing goods through its platform. Shopify's second-quarter results for the period ending June 30 show sales up an incredible 97% year-over-year to $714.3 million. The sales growth rate was only 47% in the first quarter.

Prior to Q2, Shopify's growth rate was trending down. In 2019, its sales of $1.6 billion were up 47%. The year before that, revenue was $1.1 billion and grew at a rate of 59%. And in 2017, sales of $673 million were up 73% from the previous year.

With that said, 40%-plus growth rates are still impressive. Like telemedicine, the global e-commerce market is rapidly growing. Experts estimate the industry's CAGR will be 11.34% until 2024, eventually hitting a value of more than $6 trillion.

Although Shopify's stock hit all-time highs this year, it could keep climbing as consumers opt to shop online. The challenge for Shopify will be its fight for market share. It faces  competition from big names like AmazonAdobe-owned Magento, and Facebook, where consumers can easily purchase products through Marketplace or its social networking service, Instagram.

Which stock is the better buy today?

Both of these stocks are flying high in 2020 and have outperformed the S&P 500 by wide margins since the start of the coronavirus pandemic:

SHOP Chart

SHOP data by YCharts.

It's unclear why Robinhood investors aren't as excited about these two stocks as they are about other tech and healthcare stocks. But with both companies delivering strong numbers and many growth opportunities ahead, it's not too late for Robinhood investors to jump on board.

If you can only buy one of these stocks today, go with Teladoc. The virtual care provider is in an industry that's not as established as e-commerce. The growth opportunities are much more plentiful and competition is not nearly as fierce. Many of Teladoc's competitors are private and lack the resources necessary to catch up with the telehealth giant. Teladoc is a great option for Robinhood investors who are looking for a surefire growth stock to add to their portfolios.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Adobe Systems, Amazon, Facebook, Livongo Health Inc, Shopify, and Teladoc Health and recommends the following options: short January 2022 $1940 calls on Amazon and long January 2022 $1920 calls on Amazon. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Shopify Stock Quote
$37.27 (-2.00%) $0.76
Teladoc Health Stock Quote
Teladoc Health
$27.31 (3.10%) $0.82
Meta Platforms, Inc. Stock Quote
Meta Platforms, Inc.
$109.25 (0.44%) $0.47
Amazon Stock Quote
$92.03 (-2.05%) $-1.93
Adobe Inc. Stock Quote
Adobe Inc.
$326.02 (-0.90%) $-2.95
Livongo Health Inc Stock Quote
Livongo Health Inc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.